In Brief: Wyeth-Ayerst Premarin
Wyeth-Ayerst Premarin: Duramed files citizen's petition with FDA July 31 requesting that the agency declare Premarin (conjugated estrogens) "misbranded" because each active ingredient is not identified in labeling. The generics firm asks FDA to withdraw Wyeth's conjugated estrogens NDAs if labeling is not corrected and requests that no new indications be approved until Premarin is fully characterized. FDA determined May 5 that it would not approve generic versions of Premarin until the active ingredients are sufficiently defined ("The Pink Sheet" May 12, p. 3)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth